At the European Society for Medical Oncology (ESMO) Congress this week, investigators presented data for a new and potentially important drug, ribociclib (Novartis). This oral medication is ...

The team found adding ribociclib, a drug that belongs to a class of CDK4/6 inhibitors, to standard hormone therapy not only ...

Ribociclib – a drug already used to treat breast cancer – may help slow the growth of diffuse hemispheric glioma (DHG), new research has found. Diffuse hemispheric glioma is a rare, high-grade ...

Ribociclib in combination with an aromatose inhibitor for previously untreated advanced or metastatic hormone receptor-positive, her2-negative breast cancer. The NICE appraisal committee wanted to ...

Their research suggested that neoadjuvant therapy with a combination of ribociclib and letrozole could be an alternative to multi-drug neoadjuvant chemotherapy. The trial involved high risk ...

This month, the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for breast cancer were updated to recommend ribociclib (Kisqali) as a Category 1 preferred CDK4/6 inhibitor (CDK4/6i) ...

Intracellular lipid chaperones dictate the destiny of lipids. Also known as fatty acid-binding proteins (FABPs), these are a group of proteins that coordinate lipid trafficking and signalling in ...

The US FDA has approved Kisqali (ribociclib) for treating early-stage breast cancer in combination with hormone therapy. It targets high-risk HR-positive, HER2-negative stage II and III patients ...

preventing estrogen from binding. Examples of SERMs approved by the FDA are tamoxifen (Nolvadex), raloxifene (Evista), and toremifene (Fareston). Tamoxifen has been used for more than 40 years to ...

For these cancers, hormone therapies can be prescribed to block the action of estrogen (by binding to the receptors) or lower ...

An approachable framework for the scalable implementation of proteome-wide thermal shift assays to assess drug mechanisms of action.